Risperdal

Risperdal Litigation Nears Conclusion: Over $1 Billion Settled as Philadelphia Cases Wind Down

by

Philadelphia, PA — The highly contentious Risperdal litigation, once a burgeoning mass tort in Philadelphia’s courts with a staggering 7,000 cases just five years ago, has now dwindled to a mere five. The substantial decrease in active lawsuits follows a period of intensive settlements where approximately 6,000 cases were resolved through a combined arrangement that could amount to as much as $1.1 billion. Law firms spearheading these negotiations include Pennsylvania-based Kline & Specter and Sheller PC, along with Arnold & Itkin of Texas, who have collectively notched several high-profile awards. A notable instance being the … Read more

$1.1 Billion Risperdal Settlement a Landmark Victory for Plaintiffs in Philadelphia’s Mass Tort History

by

Philadelphia, PA — The sprawling legal battle over Risperdal, once involving over 7,000 cases, has largely concluded with settlements that encompass a total of up to $1.1 billion. The litigation revolved around allegations that the drug, often prescribed off-label, led to the development of gynecomastia in young men and boys, a condition characterized by the growth of breast tissue. The resolution of these cases marked a significant moment in the city’s Complex Litigation Center, noted for handling one of the largest mass torts in its history. This litigation was notable not only for its size … Read more

Seeking Justice Beyond the Settlement: A Handful of Holdouts Challenge Risperdal Agreement

by

Philadelphia, PA – Thousands of individuals have agreed to a settlement concerning the drug Risperdal, marketed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. However, a small group has opted out, choosing instead to pursue their cases in court over the drug’s alleged side effects, including gynecomastia, a condition characterized by breast enlargement in men. Janssen Pharmaceuticals has faced criticism and legal action over its marketing practices and failure to fully disclose the side effect risks of Risperdal. This antipsychotic drug has been used in the treatment of various psychological disorders, including bipolar disorder, … Read more

Philadelphia’s Risperdal Litigation Nears End with Monumental $1.1 Billion Settlement Agreement

by

Philadelphia, PA — In what marks a significant resolution, nearly all lawsuits in Philadelphia involving the antipsychotic drug Risperdal have been settled for up to $1.1 billion. This settlement addresses claims that the drug, produced by Johnson & Johnson’s subsidiary Janssen Pharmaceuticals, led to adverse effects such as gynecomastia, a condition characterized by breast tissue enlargement in males. The legal battles, accumulating over years, primarily involved male plaintiffs who alleged that Risperdal, prescribed to treat schizophrenia and bipolar disorder, caused them to develop breasts after taking the medication. Many of the lawsuits also claimed that … Read more